ArticleMedicina (Kaunas, Lithuania)2026
Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.
Vali Aliyev, Ali Kaan Güren, Murad Guliyev, Zeliha Birsin, Murat Günaltılı, Mehmet Cem Fidan, Emir Çerme, Hamza Abbasov, Selin Cebeci, Selver Işık and 5 more
Abstract readMulticenter Study
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Vali AliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0003-0947-9348 Ali Kaan GürenDivision of Medical Oncology, Department of Internal Medicine, School of Medicine, Marmara University, Istanbul 34899, Türkiye.ORCID 0000-0002-3562-5006 Murad GuliyevDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Zeliha BirsinDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-2645-0785 Murat GünaltılıDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Mehmet Cem FidanDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Emir ÇermeDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Hamza AbbasovDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0003-1227-9996 Selin CebeciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-1758-2321 Selver IşıkDivision of Medical Oncology, Department of Internal Medicine, School of Medicine, Marmara University, Istanbul 34899, Türkiye.ORCID 0000-0002-2726-1740 Murat SarıDivision of Medical Oncology, Department of Internal Medicine, School of Medicine, Marmara University, Istanbul 34899, Türkiye.ORCID 0000-0003-0596-1559 Onur Erdem ŞahinDepartment of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Muhammet Sait SağerDepartment of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0003-2013-5845 Özkan AlanDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.ORCID 0000-0002-6635-2012 Nebi Serkan DemirciDivision of Medical Oncology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Positron Emission Tomography Computed TomographyAdultAgedAminopyridinesErb-b2 Receptor Tyrosine KinasesFemaleFluorodeoxyglucose F18HumansMiddle AgedPiperazinesPrognosisProtein Kinase InhibitorsPurinesAminopyridinesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18palbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesribociclib^18F-FDG PET/CTbreast neoplasmsCDK4/6 inhibitorsmetabolic responsemetastatic breast cancerprognosisSUVmax
Identifiers
PMID41901569
PMCPMC13027895
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390